Minimal residual disease (MRD) detection in B cell non-Hodgkin's lymphoma (NHL) patients has been shown to be possible using the rearranged heavy (IgH) chain gene as a tumor marker. To explore a second independent tumor marker, we used specific PCR primer sets to identify tumor-specific rearranged Ig light chain (IgL) genes. Rearranged IgL genes were amplified from lymphoma DNA by multiplex PCR using separate primer sets for the Ig and the Ig genes. They were considered to be of tumor origin if they were monoclonal, and if the same rearrangement was isolated from at least two independent PCR products. From 12 out of 13 intermediate-and high-grade malignant NHL, PCR products could be obtained with IgL specific primers. PCR products from five NHL were studied in detail by cloning and sequencing. The rearranged IgL genes showed 85-100% homology with their closest germ line counterparts. Intraclonal IgL sequence heterogeneity was studied in five lymphomas and detected in only one. Minimal disease was studied in three patients by PCR, followed by Southern hybridization of the PCR product with a lymphoma-specific oligonucleotide probe, which allowed for detection of lymphoma DNA following 1000-fold dilution. Blood samples from one patient, who is in long-term clinical remission, were negative for the lymphoma-specific rearranged Ig gene. In the second patient the rearranged Ig gene was detected during the first clinical remission, that was followed by a nodal relapse, but not during the second remission, that has been stable for almost 3 years now. The third patient was negative for the rearranged Ig gene in blood samples up to 102 months after diagnosis. Circulating lymphoma cells were detected in blood and bone marrow samples which were negative by morphological and immunological criteria. Our studies show that the rearranged IgL gene can be used as a second independent tumor marker in intermediate-and high-grade malignant NHL.
Introduction
Detection of minimal residual disease (MRD) in B cell nonHodgkin's lymphoma (NHL) patients may provide an early endpoint to evaluate treatment strategies aimed at cure; identify patients in clinical complete remission (CCR) who have an increased risk of relapse; and detect tumor cell contamination of autologous stem cell grafts. MRD can be detected with high sensitivity by amplification of chromosomal translocation breakpoints such as t (14;18) 1-3 by means of the polymerase chain reaction (PCR). [4] [5] [6] For those NHL that carry no known translocation, 7 rearranged immunoglobulin heavy chain (IgH) genes have been shown to provide specific tumor markers for the detection of MRD. [8] [9] [10] Rearranged IgH genes are cloned from NHL biopsies by PCR, and lymphoma-specific PCR primers or probes defined in the complementarity determining region 3 (CDR3) 11 are used for MRD detection. Although the number of patients that have been investigated is presently low, the available data suggest that IgH-PCR may be clinically useful. PCR negativity of autografts appears to correlate with molecular remission during follow-up. 9 Moreover, PCR status after autologous bone marrow transplantation was reported to predict clinical relapse in a small series of patients. 8 However, both technical difficulties and the biological characteristics of NHL impose limits on the use of the rearranged IgH gene as a lymphoma marker. Amplification of tumor-specific rearranged IgH genes from lymphoma biopsies by PCR is hampered by uncertainty with regard to the exact nucleotide sequence of the target DNA, and the presence of an oligoclonal background of normal B lymphocytes. Thus even with comprehensive primer sets, from 7-15% of NHL no rearranged IgH gene specific for the lymphoma can be amplified. 10, [12] [13] [14] [15] Furthermore, the presence of intraclonal sequence variation of the rearranged IgH gene, due to somatic hypermutation following the neoplastic event, [16] [17] [18] [19] [20] may lead to false PCR-negativity. Clones may arise that imperfectly fit the defined primers and probes, eg due to ongoing mutation or selective outgrowth of a minor clone that was missed at diagnosis. These considerations have led us to explore the use of lymphoma-specific rearranged immunoglobulin light (IgL) genes as a second, independent marker for the detection of MRD in NHL.
The immunoglobulin light chain protein is encoded by either a rearranged Ig or Ig gene. During rearrangement at the Ig locus, one out of approximately 40 potentially functional V genes 21, 22 is combined with one of the five J genes. 23 During Ig rearrangement, a choice can be made from approximately 30 functional V genes 24 and four J genes. 25, 26 Using slightly modified primer sets designed to amplify rearranged Ig and Ig genes in a multiplex PCR, 27 we obtained PCR products from 12 out of 13 intermediateand high-grade NHL. Clonality and intraclonal sequence heterogeneity of the rearranged IgL genes were investigated in five lymphomas, and MRD follow-up studies were performed in three NHL patients. These data indicate that rearranged IgL genes may provide valuable markers for MRD studies in NHL.
Materials and methods

Cloning and characterization of rearranged IgL genes from lymphoma biopsies
DNA was isolated from cryopreserved lymphoma biopsies as described previously. 28 Thirteen intermediate-or high-grade NHL were selected in which a monoclonal B cell population was detected by Southern hybridization of lymphoma DNA with a probe derived from the joining region of the immuno-globulin heavy chain gene. 29 The characteristics of these NHL patients are summarized in Table 1 .
Rearranged Ig␥ genes were amplified by PCR using a set of seven primers described by Hawkins et al. 27 The six primers used to amplify rearranged Ig were identical to published primers, 27 except HK26BACK and HK30BACK, that were replaced by 5Ј-GATATTGTGATGAC(C/T)CAG(A/T)CTCC-3Ј and 5Ј-GAAATTGTGTTGAC(A/G)CAGTCTCC-3Ј, respectively, and the J primers, that were replaced by 5Ј-GTTTGATCTCCA(C/G)(C/T)TTGGTCCC-3Ј (JK14A) and 5Ј-GTTTAATCTCCAGTCGTGTCCC-3Ј (JK50A), respectively.
Multiplex PCR was performed using the Ig and Ig primer sets separately on each lymphoma DNA sample; if this yielded inconclusive results, the PCR was repeated using a single primer from the VL region combined with a single JL primer. PCR was performed on Omnigene (Hybaid, Teddington, UK) and Robocycler gradient 40 (Stratagene, La Jolla, CA, USA) thermocyclers, in 25 l consisting of 50 mm KCl, 10 mm Tris HCl (pH 9), 0.1% Triton X-100, 0.2 mm dATP, dCTP, dGTP and dTTP, 1.5 mm MgCl 2 , 0.3 ng of each multiplex primer or 1.0 ng primer otherwise, 0.2 U Taq DNA polymerase (Promega, Leiden, The Netherlands), and 100 ng lymphoma DNA. PCR conditions were as follows: 5 min 94°C, followed by 25-30 cycles of 1 min 94°C, 1 min T a , 1 min 72°C, and subsequently 10 min 72°C. Annealing temperature, T a , depended on primer sequence and ranged between 55-65°C. PCR products were size-separated on 1.5-2% agarose gels containing ethidium bromide. The conditions for multiplex and specific PCR were the same except for the amount of primer used.
Clonality of the PCR products was assessed by sequencing of cloned products. For cloning, 1 l of PCR product or gelpurified PCR product was ligated into the TA cloning vector pCR-II (Invitrogen, Leek, The Netherlands). Purified plasmid DNA was automatically sequenced on an ABI 377 sequencer using fluorescent dye terminators as recommended by the manufacturer (Perkin Elmer, Nieuwerkerk a/d IJssel, The Netherlands), or sequenced manually using T7 DNA polymerase in the presence of radiolabeled dATP. Clones from at least two independent PCR products were analyzed. To ident- 23, 25, 26 germline genes were subsequently aligned with the rearranged IgL genes to determine the boundaries of the junction domain, using DNAMAN software (Lynnon Biosoft, Quebec, Canada).
Minimal residual disease detection
DNA isolated from heparinized peripheral blood (PB) and bone marrow (BM) samples as described previously 28 was subjected to PCR. In order to exclude false negativity due to DNA degradation or the presence of PCR inhibitors, the IL-3 gene was amplified from the samples as described. 28 If the IL-3 PCR was negative, DNA from blood and bone marrow samples were treated with heparinase (Sigma, Steinheim, Germany; 1.5 U/300 ng DNA for 1 h at 25°C). Heparinase-treated DNA was successfully amplified with the IL-3 primers, suggesting that initial negativity could be due to the presence of heparin.
Amplification of the rearranged IgL gene was performed using either VL and JL primers, or a lymphoma-specific primer defined in the CDR1 domain combined with a JL primer, as described in the legends of Figure 1 . PCR conditions were as described above, except that 300 ng target DNA was used, reaction volume was 50 l, and 30 cycles were performed. PCR products were size-separated on 1.5-2% agarose gels, blotted and hybridized to a lymphoma-specific oligonucleotide probe defined in the VL-JL junctional domain that was radiolabeled using T4 polynucleotide kinase and ␥-32 P-dATP. For lymphoma 325, the JL primer (JL23A) was combined with a specific CDR1 primer (5Ј-TGGTACTTATAATTATGTC-3Ј) and the PCR product was detected using the specific CDR3 probe (5Ј-TCCGAAGACAGAGCTGTTAC-3Ј).
Figure 1
Detection of lymphoma-specific rearranged IgL and IgH genes. For lymphoma 219, PCR was done with a JL primer combined with a primer specific for the VL family used in the rearrangement, followed by Southern hybridization of the product with a lymphoma-specific oligonucleotide probe (5Ј-CGAAAGTGACAGCACTGTACGTC-3Ј). For lymphoma 311 the results of the light and heavy chain specific PCR are shown. For the light chain specific PCR the JL primer was combined with a specific CDR1 primer (5Ј-CCAGCAGTGACGTTGGTGG-3Ј) and the PCR product was detected using the specific probe 5Ј-CCAGATCCGAAGACATATG-3Ј. Time following diagnosis is indicated in months. The sensitivity was determined by serial dilution of lymphoma DNA in DNA isolated from normal donor blood. Negative controls included DNA isolated from unrelated tumors that used the same VL family, normal peripheral blood (NPB), normal tonsil, ZR75.1 human breast epithelial cells, 42 and a no DNA control. The bone marrow was harvested from patient 311 2 months after diagnosis and re-infused 3 months later. The heavy chain PCR for samples as indicated, was performed as described previously.
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Results
Cloning of rearranged IgL genes from lymphoma biopsies
DNA isolated from biopsies of 13 patients with intermediateor high-grade malignant NHL ( Table 1 ) that contained a monoclonal B cell population as detected by Southern hybridization 10 was amplified by PCR using primers designed for rearranged IgL genes. With the limited number of PCR cycles employed, amplification products obtained from polyclonal B cells (normal donor blood leukocytes or tonsil) were visible as a faint smear on agarose gels stained with ethidium bromide. From the biopsies of 12/13 NHL patients, discrete PCR products were obtained, indicating the presence of a monoclonal B cell population. In nine NHL, the product was restricted to either Ig or Ig. In seven cases in which the Ig/Ig expression on the cell membrane was determined by immunochemistry the corresponding light chain was found by PCR (Table 1) .
Five NHL were selected for further study. Amplification product clonality was assessed by cloning of PCR products of at least two independent reactions, followed by complete sequence analysis of at least 10 individual clones. In each of these NHL, a putative lymphoma-derived rearranged IgL gene could be identified, because the majority of clones exhibited identical VL and JL germline donors and VL-JL junctional domains ( Table 2) . The rearranged IgL genes showed 85-100% homology with the most closely related germline VL and JL genes in the databases. All rearranged IgL genes were potentially functional, since they have preserved the correct open reading frame between the VL and JL primers (Table 3) . In nucleotide sequences from the five lymphomas, we found 53 mutations (12%) resulting in amino acid replacement and 25 silent mutations (6%), in the total of 447 amino acids in comparison with the respective germline sequences. The replacement mutations appear to cluster in the CDR domains (16% in CDR domain vs 10% in FR domain) in agreement with other studies. 18, 19, 31, 32 To minimize the risk of false negative results in screening MRD, intraclonal sequence heterogeneity of the rearranged IgL genes was characterized. Taking into account only the sequence variation observed in clones from independent amplifications, since other variations may be due to Taq polymerase errors, intraclonal sequence heterogeneity was limited to a single nucleotide difference within FR3 in one lymphoma (311).
Minimal residual disease detection
MRD was studied in three patients with different clinical course and a large series of follow-up samples. DNA isolated from peripheral blood and bone marrow samples was ampli- fied by PCR using the VL and JL primers that had been used in cloning of the rearranged IgL gene. PCR products were Southern blotted and hybridized with specific oligonucleotide probes overlapping the junction, because the sequence variations in the rearranged genes were rather small in comparison to their germline counterparts. Negative controls included normal donor leukocyte and tonsil DNA, as well as DNA isolated from lymphomas known to use related VL genes. This approach was successful for lymphoma 219; however, for lymphoma 311 and lymphoma 325 increased specificity was obtained by replacing the VL primer with a specific PCR primer chosen in the CDR1 region. Serial dilution of lymphoma DNA in normal blood DNA followed by PCR and Southern blotting showed detection sensitivity to be 10
, ie one lymphoma cell within 1000 normal cells. All experiments were performed at least in duplicate. Control experiments included amplification of the IL-3 gene to confirm sample quality.
Patient 219, who suffered from a diffuse follicular center lymphoma, was treated with eight courses of conventional chemotherapy. From this patient no rearranged IgH gene was amplified previously. 10 Minimal disease was studied in seven blood samples. The first sample was taken 6 months following diagnosis, prior to the seventh chemotherapy course, at which time-point the patient was in CCR. Subsequent samples were taken post-treatment at 10, 15, 17, 20 and 31 months after diagnosis. Following PCR and Southern hybridization to detect the lymphoma-specific rearranged Ig gene, all followup samples were found to be negative (Figure 1) , indicating that the number of lymphoma cells was below the detection threshold (one in 1000). Subsequent samples remained negative (not shown). Patient 219 remains in CCR for more than 7 years now.
Patient 311, who had a diffuse mixed small and large cell lymphoma, entered partial remission following chemotherapy. Transient CCR was induced by high-dose chemotherapy combined with autologous bone marrow transplantation. However, the patient suffered from nodal relapses 9, 19 and 25 months after diagnosis. Following chemotherapy and local radiotherapy, the patient achieved CCR 37 months after diagnosis, and has been in continuing remission for almost 3 years now. The lymphoma-specific Ig rearrangement was detected in the bone marrow transplant, in PB samples up to 22 months after diagnosis, and in a biopsy of the second relapse (Figure 1) . Peripheral blood samples taken 50, 64 and 67 months following diagnosis were negative, however. Similar results were obtained for the analysis of the lymphoma specific IgH rearrangement (Figure 1) .
Patient 325, who suffered from a diffuse mixed small and large cell lymphoma, entered CCR following induction chemotherapy. Thirty months after diagnosis, a nodal relapse was detected and treated by local radiotherapy, after which the patient entered CCR again. Peripheral blood samples and a bone marrow sample from this patient were negative for the lymphoma specific IgL rearrangement up to 102 months after diagnosis. This indicated that the number of tumor cells was below threshold of detection.
During the entire study period of follow-up, no tumor cells were detected by morphological and immunological examination of BM and PB samples from these patients.
Discussion
Consisting of a variable (VH), diversity (DH), and joining (JH) gene, that are often imprecisely joined because of deletions and non-template additions of nucleotides at the two junctions, the rearranged IgH gene represents a specific marker for B cell clones. Since the rearranged IgL gene originates from the assembly of only two genes (VL and JL), it is in principle less specific than the rearranged IgH gene. Nevertheless, cloning of the rearranged IgL gene appears worthwhile for several reasons. First, from a minority of NHL no rearranged IgH gene is cloned following PCR. Second, since absolute certainty regarding tumor origin of the rearranged IgH gene cloned from a lymphoma biopsy is mostly not available, an independent second marker is valuable. Third, clonal evolution of the rearranged IgH gene by somatic mutation and selection may result in the emergence of a malignant B cell clone carrying a mutant rearranged IgH gene that escapes detection by PCR with the primer/probe combination used.
Amplification of rearranged immunoglobulin genes from NHL is hampered by somatic hypermutation of the immunoglobulin gene, that may lead to false negativity, and by the presence of oligo-or polyclonal normal B cells in lymphoma biopsies, that may lead to false positivity. 10, 33 Therefore, only tumors in which a monoclonal B cell population was detected by Southern hybridization were entered in this study. Furthermore, a limited number of PCR cycles (25) (26) (27) (28) (29) (30) was performed to minimize amplification of rearranged IgL genes from nonmalignant B cells. Comparison of immunophenotyping and PCR results was possible in seven NHL, and showed complete agreement.
From the 12 out of 13 NHL from which a PCR product was detectable with IgL primers, five lymphomas were selected for clonality assessment and characterization of intraclonal sequence heterogeneity, by cloning and sequencing of at least 10 clones from two or more independent PCR amplifications. In each of the five NHL a numerically superior clone, that is considered to represent the lymphoma-specific rearranged IgL gene, could be identified. From the DNA sequence could be concluded that during rearrangement, nucleotide deletions have occurred at the VL-JL junctions of all five IgL genes (Table 3) . Furthermore, in three rearranged genes one to four nucleotides are present that do not correspond to germline VL and JL sequences. Since the rearranged IgL genes contain somatic mutations, it cannot be excluded that the nontemplate nucleotides arose by mutation, and that the VL and JL deletions assigned in Table 3 are actually smaller. However, at least in the rearranged IgL gene from lymphoma 325, in which four nontemplate nucleotides are observed, it appears likely that these are the result from terminal transferase activity. Nontemplate nucleotide addition during Ig gene rearrangement has been reported to occur both in normal [34] [35] [36] [37] and malignant 38 B cells. The rearranged IgL genes displayed 5-15% DNA sequence divergence from the most closely related germline VL genes. 22, 24, 39 For four of the NHL studied, the range in mutations (5-8%) is comparable to that observed in the rearranged IgL genes from normal B cells, 37, 40 and in the rearranged IgH genes from the same NHL. 10 The 15% mutation frequency observed in the rearranged Ig gene from lymphoma 219 clearly falls outside the normal range. Although most germline VL genes appear to be cloned, it cannot be excluded that this rearranged gene is derived from a novel V germline clone, but it is most likely that this tumor shows a high frequency of somatic mutations. In this context, it is interesting to note that in this lymphoma no immunoglobulin expression was detected by immunocytochemistry, and that IgH cloning was not successful, 10 suggesting that the rearranged IgH gene of this lymphoma may also be heavily mutated.
Rearranged immunoglobulin genes from low-grade NHL have been reported to exhibit intraclonal sequence variation, [16] [17] [18] [19] [20] apparently due to somatic hypermutation subsequent to neoplastic transformation. However, in intermediate-and high-grade NHL, intraclonal sequence heterogeneity of rearranged IgH genes appears limited. 10 In more than 50 clones of rearranged IgL genes from five intermediate-and high-grade NHL only a single nucleotide difference was observed, in lymphoma 311. This tumor also gave clear evidence for clonal evolution of the rearranged IgH chain. 10 Intraclonal sequence variation appears limited in IgL genes also. Therefore clonal evolution of rearranged heavy and light chain immunoglobulin genes, that may lead to false negative results during MRD studies, appears less of a problem in intermediate-and high-grade NHL than in follicular low-grade NHL.
MRD was studied in three patients with different clinical course. The first patient (219) entered long-term CCR following induction chemotherapy. No lymphoma-specific rearranged IgL genes were detected in blood samples from this patient. In blood samples from the second patient (311) lymphoma-specific rearranged IgL genes were detected during first (transient) CCR, but not during second (long-term) CCR, in complete agreement with the results obtained using the rearranged IgH gene as a marker (Figure 1) . The third patient (325) entered CCR following induction chemotherapy, until at 30 months a nodal relapse was detected and treated, upon which the patient entered CCR again. At 10 −3 detection sensitivity (determined by dilution of lymphoma DNA in peripheral blood DNA) no lymphoma-specific rearranged IgL genes could be detected. This is not unexpected since the heavy chain rearranged gene 10 was borderline detectable at a sensitivity of 10 −4 . The results from the four patients studied thus far (this paper and Ref. 10) suggest that Ig-PCR negativity correlates with long-term CCR. These data agree with two recent studies in which relapses were only observed in IgH-PCR positive patients. 8, 9 Although positivity may not invariably predict relapse, 41 the present data indicate that rearranged immunoglobulin genes may be clinically relevant MRD markers.
We have presented data which show that NHL-specific markers may be generated from rearranged IgL genes. Evidence of tumor origin of rearranged IgL genes is less strong in this study than that of rearranged IgH genes, for which amplification with independent non-overlapping VH primers was required as additional proof. 10 This limitation may be overcome by definition of a non-overlapping VL primer set for the generation of an independent PCR product. Another disadvantage is the lower detection sensitivity of rearranged IgL genes (10 −3 ) as compared to IgH genes (10 −4 ), that may result from the lower variability inherent to IgL rearrangement, and/or from the use of oligonucleotide probes. Although the rearranged IgH gene appears the marker of choice for MRD studies in NHL that lack known chromosomal translocations, the rearranged IgL gene may be valuable for lymphomas from which no rearranged IgH gene is cloned, as a second independent marker, or as an additional target for anti-idiotype immune therapy.
